The recently discovered serum marker He4 appears superior to CA125 in differentiating benign from malignant ovarian masses both in pre- and postmenopausal women [14, 34, 35]; studies have shown increased values in 50% of ovarian cancer patients who do not express CA125 [36]. This evidence concerns the gene WFDC2 and ovarian carcinoma.